You have 9 free searches left this month | for more free features.

Immunoconjugates

Showing 26 - 50 of 113

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer Trial in United States (drug,

Recruiting
  • Early-stage Breast Cancer
  • +6 more
  • Fullerton, California
  • +8 more
Sep 19, 2022

Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Haven (procedure, drug, biological)

Recruiting
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm
  • Biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jan 25, 2023

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,

Recruiting
  • High Grade Serous Ovarian Cancer
  • +2 more
  • Upifitimab rilsodotin
  • Placebo
  • Phoenix, Arizona
  • +40 more
Jan 25, 2023

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Metastatic Colorectal Cancer Trial (IMMU 130)

Withdrawn
  • Metastatic Colorectal Cancer
  • IMMU 130
  • (no location specified)
Aug 12, 2021

Malignant Glioma Trial in Durham (D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three

Recruiting
  • Malignant Glioma
  • D2C7-IT (6920 ng/mL via convection-enhanced delivery)
  • +2 more
  • Durham, North Carolina
    Duke University Medical Center
Mar 22, 2022

Breast Tumors, Gastric Tumor, Solid Tumors Trial in Australia, United States (ARX788)

Recruiting
  • Breast Neoplasms
  • +2 more
  • Los Angeles, California
  • +8 more
Feb 25, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States

Recruiting
  • Endometrial Serous Adenocarcinoma
  • +2 more
  • Biopsy
  • +3 more
  • Phoenix, Arizona
  • +3 more
Feb 2, 2023

Solid Tumor Trial in United States (OBT076, a CD205-directed antibody-drug conjugate)

Recruiting
  • Solid Tumor
  • OBT076, a CD205-directed antibody-drug conjugate
  • Los Angeles, California
  • +5 more
Jan 10, 2022

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

Triple-negative Breast Cancer Trial (IMMU-132 infusion is administered to participants in one arm for the study, IMMU-132 plus

Withdrawn
  • Triple-negative Breast Cancer
  • IMMU-132 infusion is administered to participants in one arm for the study
  • IMMU-132 plus Carboplatin infusion
  • (no location specified)
Aug 12, 2021

Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Withdrawn
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +3 more
  • Yuma, Arizona
  • +5 more
May 25, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Relapsed/Refractory Multiple Myeloma Trial in Worldwide (Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose

Completed
  • Relapsed/Refractory Multiple Myeloma
  • Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
  • Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
  • Phoenix, Arizona
  • +10 more
Mar 25, 2022

CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker

Recruiting
  • CD30-Positive Neoplastic Cells Present
  • Malignant Mesothelioma
  • Brentuximab Vedotin
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Jan 3, 2022

Metastatic Triple Negative Breast Cancer Trial (Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy

Withdrawn
  • Metastatic Triple Negative Breast Cancer
  • (no location specified)
Jan 24, 2022

Breast Cancer, Non-small Cell Lung Carcinoma Trial in Worldwide (Trastuzumab deruxtecan (DS-8201a), Pembrolizumab)

Recruiting
  • Breast Cancer
  • Non-small Cell Lung Carcinoma
  • San Francisco, California
  • +24 more
Nov 30, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate Cancer
  • FOR46
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 1, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,

Active, not recruiting
  • Classic Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Duarte, California
  • +5 more
Mar 17, 2022